Hepatitis C Virus (HCV): Structure, Life Cycle, Immunity, and Therapeutics

Hepatitis C Virus (HCV): Overview

Introduction

Hepatitis C Virus (HCV) is a major human pathogen responsible for significant global morbidity and mortality. It is a member of the Flaviviridae family and is primarily associated with liver disease, including chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC).

• Family: Flaviviridae (enveloped, positive-sense RNA viruses)

• Genus: Hepacivirus

• Global Impact: Pandemic distribution, with approximately 3% of the world population seropositive and 71.1 million actively infected individuals.

• Transmission: Bloodborne (transfusions, IVDU), less commonly sexual or vertical.

Flaviviridae Family and HCV Classification

Family Tree and Genera

• Order: Picornavirales

• Genera: Pestivirus, Hepacivirus, Pegivirus, Flavivirus

• Contains over 70 medically/veterinary important pathogens.

Example: Other notable members include Dengue virus, Yellow fever virus, and Zika virus.

HCV Structure and Genome Organization

Virion Structure

• HCV is an enveloped virus, 50–80 nm in diameter.

• It forms a lipoviral particle by associating with host lipoproteins, aiding immune evasion.

• Immune Evasion: Lipids shield the virus from neutralizing antibodies.

Genome Organization

• Single-stranded, positive-sense RNA genome (~9,600 bases).

• Contains a single open reading frame (ORF) flanked by 5' and 3' untranslated regions (UTRs).

• Encodes 10 proteins: structural (Core, E1, E2) and non-structural (p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B).

Functions of HCV Proteins

• Core: Capsid formation

• E1/E2: Envelope glycoproteins (host cell entry)

• p7: Ion channel, assembly factor

• NS2: Autoprotease, assembly

• NS3: Serine protease, helicase, assembly

• NS4A: Protease cofactor

• NS4B: Replication complex formation

• NS5A: Assembly, immunomodulation

• NS5B: RNA-dependent RNA polymerase

HCV Life Cycle

Stages of the Viral Life Cycle

1. Entry: Virus binds to host receptors (e.g., CD81, SR-BI, claudin-1, occludin) and enters hepatocytes.

2. Uncoating: Release of viral RNA into the cytoplasm.

3. Translation and Polyprotein Processing: Viral RNA is translated into a polyprotein, which is cleaved into functional proteins.

4. Replication: Occurs in the membranous web; NS5B synthesizes new RNA genomes.

5. Assembly and Release: New virions are assembled and released, often associated with lipoproteins.

Example: The NS3/4A protease is a key target for antiviral drugs due to its role in polyprotein processing.

Cell Tropism and Transmission

Cell Types Infected by HCV

• Primary: Hepatocytes (liver cells)

• Others: Intestinal enterocytes, B lymphocytes, astrocytes

Modes of Transmission

• Within host: Cell-to-cell spread

• Between hosts: Blood transfusion, contaminated blood products, injecting drug use, needle stick injury

• Sexual transmission: Low risk

Clinical Outcomes and Pathogenesis

Outcomes of HCV Infection

• ~20%: Spontaneous resolution (acute infection cleared)

• ~80%: Progress to chronic infection

Chronicity and Disease Progression

• Chronic hepatitis C can lead to fibrosis, cirrhosis (25% over 20–30 years), and hepatocellular carcinoma (HCC).

• End-stage liver disease and death are possible outcomes.

Natural History

• Progression: Healthy liver → Chronic hepatitis C → Cirrhosis → HCC/Decompensated cirrhosis/Death

Extrahepatic Manifestations

• Cryoglobulinemic vasculitis, B-cell lymphoma, cardiovascular disease, renal disease, insulin resistance, and pruritus.

HCV Phylogenetics and Global Distribution

Genotypes and Subtypes

• 8 major genotypes (GT1–GT8), >93 subtypes

• Genotypes differ by 30–35% at the nucleotide level; subtypes by 15–20%

Global Prevalence

• Highest prevalence in Africa and parts of Asia

• Genotype distribution varies by region

Immunity and Immune Evasion

Immune Responses to HCV

• Innate Immunity: Type I and III interferons (IFNs) are critical for viral control and clearance.

• Adaptive Immunity: Strong, broad, and durable HCV-specific T cell responses are essential for viral clearance.

• B cells and Antibodies: Early neutralizing antibodies may aid in acute infection clearance, but their role is less clear in chronic infection.

Mechanisms of Immune Evasion

• Lipid shielding of virions

• High genetic variability (quasispecies)

• Mutations in epitopes targeted by neutralizing antibodies and T cells

• Expression of inhibitory molecules leading to T cell exhaustion

Table: Correlates of Immunity vs. Mechanisms of Evasion

Correlates of Protective Immunity	Mechanisms of Viral Immune Evasion
Neutralizing antibodies to E1/E2	Viral escape mutations
Strong CD4+ and CD8+ T cell responses	Inhibition of interferon response
Broad T cell responses to NS3/NS5	T cell exhaustion (PD-1 upregulation)

Therapeutics and Vaccine Development

Antiviral Therapies

• Former standard: Pegylated IFN-α + Ribavirin (RBV), 48–72 weeks, ~20% cure rate, significant side effects

• Direct-acting antivirals (DAAs): Target NS3/4A protease, NS5A, NS5B polymerase; >95% cure rates, shorter duration, fewer side effects

• Combination therapy: Reduces resistance and improves efficacy

• Access: 80% of global patients lack access due to high cost

Vaccine Development

• No current safe, effective, and affordable vaccine

• mRNA-based vaccines are under evaluation

Patient Prognosis After Cure

• Reduced all-cause and liver-related mortality

• Regression of fibrosis possible

• Ongoing surveillance needed for advanced fibrosis/cirrhosis

Key Questions and Answers

• Which HCV antiviral inhibits serine protease activity? Answer: Grazoprevir (NS3/4A protease inhibitor)

• Which HCV protein interacts with CD81 on target cells? Answer: E2 glycoprotein

• What is the size of the HCV genome? Answer: 9,600 bases

• What is the genome of HCV? Answer: Single-stranded RNA with positive polarity

Summary and Future Prospects

• IFN-free treatment protocols are now standard in many regions

• Global eradication campaigns are underway, but access remains a challenge

• Unmet need for a safe, effective, and affordable vaccine

• Improved drug formulations and access are priorities for the future